Tag: Boehringer Ingelheim
University of Sydney spinout bags $273m for psychiatric drug dev’t
Kinoxis Therapeutics, a University of Sydney spinoff, announced a partnership with German pharmaceutical company Boehringer Ingelheim to develop precision therapies that target oxytocin aimed at enhancing the quality of life for people with psychiatric disorders.
Global pharma giants join forces with Aussie research institutions to develop new cancer treatments
Two global pharmaceutical firms have teamed up with Australian research institutions to develop new treatments and drugs to fight cancer.
German pharma giant Boehringer Ingelheim...
Featured Article
Good Design Australia opens entries for 2026 awards
For more than six decades, Good Design Australia has celebrated the power of design to shape innovation, industry, and everyday life. Its flagship program, the Australian Good Design Awards, recognises projects that show how thoughtful design can enhance products, services, systems, and communities.
